Unlock the future of immunotherapy. For decades, traditional antibody drugs were limited to tagging a single target. Now, meet the Bispecific Antibody (BsAb): a revolutionary molecule engineered to simultaneously grab two different targets, acting as a molecular "handcuff" to drag your immune system's most powerful killer, the T cell, directly to the cancer cell.
In this episode, we trace the incredible scientific journey of BsAbs: from the manufacturing failure of the Quadroma Problem to the engineering solution of the "Knobs-into-Holes" strategy and the super-potent BiTE format. You'll hear how drugs like Blinatumomab have become "off-the-shelf" T-cell therapies, transforming treatment for blood cancers. We also explore the challenges of managing side effects like Cytokine Release Syndrome (CRS) and the promise of using BsAbs to conquer solid tumors. If you want to understand the sharp edge of modern cancer research, this is a must-listen.
🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!
https://linktr.ee/maneadkhin
#BispecificAntibodies #Immunotherapy #CancerResearch #BiotechBreakthrough #Oncology #TCellEngager #SciencePodcast #DrugDiscovery #PetriDishPerspectives
© 2025 Petri Dish Perspectives LLC. All rights reserved.
